16 Apr 2021

Supporting Small and emerging pharma through collaboration and specialized expertise

PDF 97 kB

Growth in the pharmaceutical industry is no longer exclusively driven by large pharmaceutical companies. The switch in the marketplace from a focus on blockbuster drugs to an emphasis on therapies that treat orphan and rare diseases has led to the rise of small and emerging pharma companies founded to advance novel medicines for specialized patient populations. These innovators require the support of contract service providers that recognize their unique requirements.

Content provided by our supplier

Grifols International, S.A.

  • ES
  • 2015
    On CPHI since
  • 4
  • 5000+
Company types
Contract Service
Primary activities
Contract Manufacturer

Other Content from Grifols International, S.A. (2)

  • Brochure Grifols Partnership - Parenterals CDMO - Flyer

    Grifols Partnership is a contract development and manufacturing platform (CDMO) focused on added value injectable products, with a large, international experience in the development and manufacturing of many types of sterile drug products. We specialize in small molecule intravenous solutions and offer high quality pharmaceutical development and product manufacturing. Our portfolio also includes products which require careful design and assembly, including medical devices and bags for blood storage and collection.
  • Video Grifols Partnership - Company presentation

    Grifols Partnership is a business to business contract development and manufacturing platform for sterile solutions (small molecules) with over 75 years of experience in producing high-quality intravenous solutions for the pharmaceutical industry worldwide.

    Watch our video and learn more about our contract manufacturing services.